Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: Placebo identical to BI 10773 high dose
Drug: Placebo identical to BI 10773 low dose

First Posted Date: 2010-07-09

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1504

Registration Number: NCT01159600

Locations: 🇨🇦
1245.23.20033 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇺🇸
1245.23.10001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸
1245.23.10127 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States

and more 145 locations

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Terminated

Conditions: Venous Thromboembolism
Arthroplasty, Replacement

Interventions: Drug: dabigatran

First Posted Date: 2010-06-30

Last Posted Date: 2023-10-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 167

Registration Number: NCT01153698

Locations: 🇦🇹
1160.118.43007 Boehringer Ingelheim Investigational Site, Wien, Austria
🇦🇹
1160.118.43004 Boehringer Ingelheim Investigational Site, Braunau, Austria
🇦🇹
1160.118.43016 Boehringer Ingelheim Investigational Site, Stolzalpe, Austria

and more 4 locations

Relative Bioavailability of Olodaterol and Fluconazole

Phase 1

Completed

Conditions: Healthy
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BI 1744
Drug: Fluconazole

First Posted Date: 2010-06-30

Last Posted Date: 2014-06-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 35

Registration Number: NCT01153724

Locations: 🇩🇪
1222.48.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Relative Bioavailability of of Olodaterol and Ketoconazole

Phase 1

Completed

Conditions: Healthy
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: BI 1744
Drug: Ketoconazole

First Posted Date: 2010-06-30

Last Posted Date: 2014-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01153711

Locations: 🇩🇪
1222.47.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: BIBW 2992
Drug: Cetuximab

First Posted Date: 2010-06-29

Last Posted Date: 2014-06-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 94

Registration Number: NCT01152437

Locations: 🇬🇧
1200.74.44009 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧
1200.74.44005 Boehringer Ingelheim Investigational Site, Bristol, United Kingdom
🇬🇧
1200.74.44003 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom

and more 10 locations

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Tiotropium 5 µg q.d.
Drug: Placebo
Drug: Tiotropium 2.5 µg b.i.d

First Posted Date: 2010-06-29

Last Posted Date: 2024-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 94

Registration Number: NCT01152450

Locations: 🇱🇻
205.420.37101 Boehringer Ingelheim Investigational Site, Riga, Latvia
🇱🇻
205.420.37103 Boehringer Ingelheim Investigational Site, Riga, Latvia
🇦🇹
205.420.43001 Boehringer Ingelheim Investigational Site, Wels, Austria

and more 12 locations

Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 135585
Drug: Placebo to BI 135585

First Posted Date: 2010-06-22

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01146886

Locations: 🇩🇪
1283.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727

First Posted Date: 2010-06-17

Last Posted Date: 2019-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT01145885

Locations: 🇭🇺
1230.23.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

Phase 1

Terminated

Conditions: Healthy
Pain

Interventions: Drug: BI 660848
Drug: Placebo

First Posted Date: 2010-06-16

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01145014

Locations: 🇩🇪
1284.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Drug Use Survey of RESPIMAT in Patients With COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2010-06-16

Last Posted Date: 2014-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 361

Registration Number: NCT01145053

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy